ES2181017T3 - Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol. - Google Patents

Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.

Info

Publication number
ES2181017T3
ES2181017T3 ES97935871T ES97935871T ES2181017T3 ES 2181017 T3 ES2181017 T3 ES 2181017T3 ES 97935871 T ES97935871 T ES 97935871T ES 97935871 T ES97935871 T ES 97935871T ES 2181017 T3 ES2181017 T3 ES 2181017T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
polyethylene glycol
osteogenesis
promoting substance
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97935871T
Other languages
English (en)
Inventor
Tetsuo Hoshino
Kazuhiro Saito
Susumu Iwasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2181017T3 publication Critical patent/ES2181017T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION SUMINISTRA UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA SUBSTANCIA NO PEPTIDICA PROMOTORA DE LA OSTEOGENESIS Y UN GLICOL DE POLIETILENO O UN DERIVADO DEL MISMO, QUE PUEDE UTILIZARSE DE FORMA VENTAJOSA COMO AGENTE PARA LA PREVENCION O EL TRATAMIENTO DE DIFERENTES ENFERMEDADES DE LOS HUESOS (POR EJ. LA OSTEOPOROSIS) EN VISTA DE LA ALTA CAPACIDAD DE ABSORCION ORAL Y DE LA GRAN ESTABILIDAD DEL INGREDIENTE ACTIVO.
ES97935871T 1996-08-26 1997-08-25 Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol. Expired - Lifetime ES2181017T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22344396 1996-08-26
JP9040897 1997-04-09

Publications (1)

Publication Number Publication Date
ES2181017T3 true ES2181017T3 (es) 2003-02-16

Family

ID=26431895

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97935871T Expired - Lifetime ES2181017T3 (es) 1996-08-26 1997-08-25 Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.

Country Status (9)

Country Link
US (1) US6190695B1 (es)
EP (1) EP0949927B1 (es)
AT (1) ATE226078T1 (es)
AU (1) AU3868997A (es)
CA (1) CA2264131A1 (es)
DE (1) DE69716469T2 (es)
ES (1) ES2181017T3 (es)
ID (1) ID18079A (es)
WO (1) WO1998008517A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
AU4165699A (en) * 1998-06-15 2000-01-05 Takeda Chemical Industries Ltd. Composition for treating cartilage disease
WO2000008018A1 (fr) 1998-08-07 2000-02-17 Takeda Chemical Industries, Ltd. Derives de benzothiepine, leur procede de preparation et leurs utilisations
CA2340165A1 (en) * 1998-08-12 2000-02-24 Haruhiko Makino Enhancer of cell differentiation induction factor
CA2378486A1 (en) * 1999-08-05 2001-02-15 Takashi Kurasawa Osteogenesis promoter sustained-release paste
EP1293197A1 (en) * 2000-06-23 2003-03-19 Takeda Chemical Industries, Ltd. Process for producing phospholipid-containing drugs
JP4176475B2 (ja) * 2001-01-19 2008-11-05 博徳 山本 内視鏡用注射剤
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US8158685B2 (en) * 2004-07-02 2012-04-17 Gregory Gene Steiner Method for bone growth
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
DK2148684T3 (da) * 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
US20100144684A1 (en) 2007-04-25 2010-06-10 Proventiv Therapeutics, Inc. Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease
EP2148685A4 (en) * 2007-04-25 2010-07-28 Cytochroma Inc METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
EP2762132A1 (en) * 2007-04-25 2014-08-06 Cytochroma Inc. Controlled Release 25-Hydroxyvitamin D
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
TWI747893B (zh) 2016-03-28 2021-12-01 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 維生素ｄ治療之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
NZ231939A (en) 1988-12-28 1991-07-26 Takeda Chemical Industries Ltd Benzothiopyran derivatives and medicaments
ATE203020T1 (de) * 1990-05-30 2001-07-15 Takeda Chemical Industries Ltd Schwefel enthaltende heterocyclische verbindungen
AU6586394A (en) * 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
JP3319625B2 (ja) * 1993-05-12 2002-09-03 ホーユー株式会社 速崩壊性生薬製剤
TW403757B (en) * 1994-12-28 2000-09-01 Takeda Chemical Industries Ltd Optically active benzothiepin derivative, its preparation and use
RU2188011C2 (ru) * 1995-06-05 2002-08-27 Такеда Кемикал Индастриз, Лтд. Активирующая остеогенез фармацевтическая композиция

Also Published As

Publication number Publication date
DE69716469T2 (de) 2003-02-20
EP0949927A2 (en) 1999-10-20
EP0949927B1 (en) 2002-10-16
WO1998008517A3 (en) 1998-05-07
ID18079A (id) 1998-02-26
DE69716469D1 (de) 2002-11-21
US6190695B1 (en) 2001-02-20
WO1998008517A2 (en) 1998-03-05
ATE226078T1 (de) 2002-11-15
CA2264131A1 (en) 1998-03-05
AU3868997A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
ES2181017T3 (es) Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.
AR015946A1 (es) Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis
AR020055A1 (es) Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma.
GT199700009AA (es) Terapia combinada para la osteoporosis
DE69910230D1 (de) Paclitaxel enthaltende arzneimittel
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
SE9901272D0 (sv) New improved formulation
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
DE69530926D1 (de) Mittel zur förderung des haarwachstums
DK0679393T3 (da) Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol
ATE395071T1 (de) Pharmazeutische zubereitungen zur angiogenese- therapie
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
PT1150681E (pt) Utilizacao de uma composicao farmaceutica que contem desoxipeganina para o tratamento da dependencia da nicotina
ES2041243T3 (es) Aplicacion de por lo menos un principio activo inhibidor o destructor de por lo menos un ser vivo unicelular o virus.
DE69817379D1 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
HRP20000781B1 (en) Effervescent preparations
EP1084710A4 (en) DRUGS AGAINST MALE STERILITY
ATE208402T1 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren